Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Iris prolapse during phacoemulsification: causes, prevention and treatment

Poster Details

First Author: R.Horta BRAZIL

Co Author(s):                        

Abstract Details

Purpose:

The purpose is to present several cases of this surgical complication, make comments about the probable causes, explain how to prevent it in certain patients, and show different forms of treatment according to the severity.

Setting:

Private practice at Instituto de Olhos Rogério Horta, Rio de Janeiro, Brazil.

Methods:

From January, 2013 to December, 2014, 6 eyes of 6 patients, in a group of 1.200 cataract surgeries, had iris prolapse during phacoemulsification. All the surgeries were performed by the author. Those iris prolapse manifested in different grades of severity, and the surgeon treated the cases in various forms. We analysed the files of the patients and found out that there were diverse causes for this complication.

Results:

The causes of prolapse were glaucoma and flat anterior chamber in three patients, the use of Tamsulosin in two of them, and one cause was unknown. For resolution, only a single prolapse reduction maneuver was necessary in two eyes. Other two eyes needed repetitive handling of the iris that caused some damage to the iris tissue, and in the other two the iris manipulation was impossible due to the increased vitreous pressure. In those last situations, a Pars Plana Vitrectomy was performed, and we could proceed with the surgeries. None of them had a capsule rupture or another complication.

Conclusions:

The cataract surgeons should know the different causes of the Iris Prolapse, how to prevent it and treat properly, in order to minimize the sequels.

Financial Disclosure:

NONE

Back to Poster listing